Clinical Trial Update: An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating safety and efficacy of leniolisib in Japanese patients with APDS (APDS gene mutation).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Activated Pi3k-delta Syndrome
• Apds

Drugs mentioned

• Leniolisib (leniolisib)

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: APDS Gene Mutation | Phase 3 | Status: UNKNOWN